Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31360409 | 1.00 | SCN9A (0.42) | SCN9AALOX5APFEN1SMN1; SMN2DPP4 | |
| SCHEMBL25156670 | 1.00 | SCN9A (0.42) | SCN9AALOX5APFEN1SMN1; SMN2DPP4 | |
| SCHEMBL30344047 | 0.90 | SCN9A (0.45) | SCN9AALOX5APFEN1DPP4F2RL3 | |
| SCHEMBL25156465 | 0.90 | SCN9A (0.45) | SCN9AALOX5APFEN1DPP4F2RL3 | |
| SCHEMBL31360255 | 0.84 | LMNA (0.37) | ALOX5APSMN1; SMN2F2RL3LMNANPSR1 | |
| SCHEMBL30344383 | 0.84 | LMNA (0.37) | ALOX5APSMN1; SMN2F2RL3LMNANPSR1 | |
| SCHEMBL25155387 | 0.81 | ALOX5AP (0.43) | ALOX5APFEN1LMNANPSR1GPR119 | |
| SCHEMBL31360281 | 0.81 | ALOX5AP (0.43) | ALOX5APFEN1LMNANPSR1GPR119 | |
| SCHEMBL25156353 | 0.81 | ALOX5AP (0.43) | ALOX5APFEN1LMNANPSR1GPR119 | |
| SCHEMBL30344023 | 0.81 | ALOX5AP (0.43) | ALOX5APFEN1LMNANPSR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | SCN9A 1682/4885ALOX5AP 456/4885FEN1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.